| ATC code C: Cardiovascular system | 
|---|
  | 
| Other ATC codes | 
ATC code C Cardiovascular system is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QC.[5] 
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
- ↑ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
 - ↑ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
 - ↑ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
 - ↑ "ATC/DDD Index 2022: code C". WHO Collaborating Centre for Drug Statistics Methodology.
 - ↑ "ATCvet Index 2022: code QC". WHO Collaborating Centre for Drug Statistics Methodology.
 
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System  | |
|---|---|
| gastrointestinal tract / metabolism (A)  | |
| blood and blood forming organs (B)  | |
| cardiovascular system (C)  | |
| skin (D) | |
| genitourinary system (G)  | |
| endocrine system (H)  | |
| infections and infestations (J, P, QI)  | |
| malignant disease (L01–L02)  | |
| immune disease (L03–L04)  | |
| muscles, bones, and joints (M)  | |
| brain and nervous system (N)  | 
  | 
| respiratory system (R)  | |
| sensory organs (S) | |
| other ATC (V) | |
  | |
| Bufadienolides | 
  | ||||||
|---|---|---|---|---|---|---|---|
| Cardenolides | 
  | ||||||
  | |||||||
| Channel blockers | 
  | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receptor agonists and antagonists  | 
  | ||||||||||||
| Ion transporters | 
  | ||||||||||||
  | |||||||||||||
Cardiac stimulants excluding cardiac glycosides (C01C)  | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenergic and dopaminergic agents  | 
  | ||||||||||||||
| Phosphodiesterase inhibitors (PDE3I) | |||||||||||||||
| Other cardiac stimulants | |||||||||||||||
  | |||||||||||||||
| Nitrovasodilators | |
|---|---|
| Quinolone vasodilators | |
| Others | |
  | |
| Sympatholytics (antagonize α-adrenergic vasoconstriction)  | |||||
|---|---|---|---|---|---|
| Other antagonists | 
  | ||||
  | |||||
| Nitrovasodilator (arterioles and venules) | |
|---|---|
| Hydrazinophthalazines (arterioles) | |
| Potassium channel openers (arterioles) | |
| Calcium channel blockers (arterioles) | 
  | 
  | |
| Sulfonamides (and etacrynic acid)  | 
  | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Potassium-sparing (at CD) | 
  | ||||||||
| Osmotic diuretics (PT, DL) | |||||||||
| Vasopressin receptor inhibitors (DCT and CD)  | |||||||||
| Other | |||||||||
| Combination products | |||||||||
  | |||||||||
| Phenylethanolamine derivatives | |
|---|---|
| Alpha blockers | 
  | 
| Niacin and derivatives | |
| Purine derivatives | |
| Ergot alkaloids | |
| Other peripheral vasodilators | |
| Antihemorrhoidals for topical use | 
  | ||||||
|---|---|---|---|---|---|---|---|
| Antivaricose therapy | 
  | ||||||
| Capillary stabilising agents | 
  | ||||||
| β, non-selective | |
|---|---|
| β1-selective | |
| β2-selective | |
| α1- + β-selective | |
  | |
| Calcium | 
  | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Potassium | 
  | ||||||||||||||||||||||||
| Sodium | 
  | ||||||||||||||||||||||||
| Chloride | 
  | ||||||||||||||||||||||||
| Others | 
  | ||||||||||||||||||||||||
See also: Receptor/signaling modulators • Transient receptor potential channel modulators  | |||||||||||||||||||||||||
| ACE inhibitors ("-pril")  | 
  | 
|---|---|
| AIIRAs ("-sartan")  | |
| Renin inhibitors ("-kiren")  | |
| Dual ACE/NEP inhibitors | 
  | 
| Neprilysin inhibitors | |
  | |
| GI tract | 
  | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liver | 
  | ||||||||||||
| Blood vessels | 
  | ||||||||||||
| Combinations | |||||||||||||
| Other | |||||||||||||
  | |||||||||||||
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.